13 completed, 5 not yet recruiting, 3 recruiting, 2 unknown. 13 Phase 4, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Completed 9, Recruiting 2, Unknown 2 |
| Not applicable | 1 | Terminated 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Getz Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CGM Experience, Preferences & Blood Glucose Parameters CGM - Diabete Mellitus, Type2diabetes | Not yet recruiting | Getz Pharma | 75 | 2026-09-10 | 2026-05-26 | |
| Faisalabad Initiative of Research and Management of NCDs Diabete Mellitus, Hypertension | Not yet recruiting | Getz Pharma | 3000 | 2026-08-01 | 2026-06-30 | |
| Acotiamide vs Itopride in Postprandial Distress Syndrome Acotiamide - Postprandial Distress Syndrome | Phase 3 | Not yet recruiting | Getz Pharma | 152 | 2025-10-30 | 2025-09-23 |
| Diabetes Foot Africa Region Registry Diabetes | Not yet recruiting | Getz Pharma | 2000 | 2025-08-01 | 2025-06-22 | |
| Classification of Adult-onset Diabetes in Five Subgroups in Pakistani Population Diabetes Mellitus, Diabetes Mellitus, Adult-Onset | Not yet recruiting | Getz Pharma | 394 | 2025-02-01 | 2024-11-26 | |
| Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi Tamsulosin Oral Capsule - Ureteric Stone of Lower Third of Ureter | Phase 4 | Completed | Getz Pharma | 240 | 2024-09-01 | 2025-08-20 |
| Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial Warfarin, Rivaroxaban 20 MG Oral Tablet, Apixaban 5mg or 2.5mg oral tablet - Left Ventricular Thrombus | Phase 4 | Unknown | Peshawar Institute of Cardiology | 141 | 2023-05-01 | 2023-08-02 |
| Pakistan Study of Premature Coronary Atherosclerosis in Young Adults Atherosclerotic Plaque, Diabetes Mellitus, Type 2 | Recruiting | Tabba Heart Institute | 2000 | 2023-03-15 | 2023-04-07 | |
| Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD Ertugliflozin 5 mg, 15mg - Liver Fat, Liver Fibrosis | Phase 4 | Recruiting | Getz Pharma | 164 | 2023-03-01 | 2025-03-21 |
| Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study Combinations of Oral Blood Glucose Lowering Drugs - Efficacy, Safety | Completed | Getz Pharma | 190 | 2022-12-01 | 2025-03-20 | |
| Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver Pioglitazone, Empagliflozin, Pioglitazone + Empagliflozin - Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis | Phase 4 | Unknown | Getz Pharma | 123 | 2021-09-15 | 2022-03-18 |
| Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study Empagliflozin - Type II Diabetes Mellitus, Efficacy, Self | Phase 4 | Recruiting | Getz Pharma | 2000 | 2021-04-01 | 2026-01-22 |
| Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients Metformin / Sitagliptin Oral Tablet - Quality of Life, Type 2 Diabetes | Phase 4 | Completed | Getz Pharma | 188 | 2021-01-01 | 2022-05-04 |
| Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus Insulin - Adverse Drug Event, Effect of Drug | Phase 4 | Completed | Getz Pharma | 238 | 2021-01-01 | 2023-02-06 |
| Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus Empagliflozin, Vildagliptin - Type 2 Diabetes | Phase 4 | Completed | Getz Pharma | 120 | 2020-07-01 | 2022-05-03 |
| Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus Empagliflozin, Usual care group - Type II Diabetes Mellitus | Phase 4 | Completed | Getz Pharma | 244 | 2019-06-01 | 2020-12-11 |
| Direct Acting Anti-Viral's In Chronic HCV Patients Sofosbuvir - Safety Issues | Completed | Getz Pharma | 511 | 2018-05-15 | 2020-12-11 | |
| Knowledge and Practices of ADR Reporting in LMICs Adverse Reaction | Completed | Getz Pharma | 1500 | 2017-04-01 | 2020-03-10 | |
| Effect of Ivabradine in Lowering Heart Rate and Quality of Life in Chronic Heart Failure Patients Ivabradine - Chronic Heart Failure | Completed | Getz Pharma | 50 | 2016-12-01 | 2018-10-17 | |
| Zurig (Febuxostat) 40mg Efficacy and Safety Trial Febuxostat, Allopurinol - Hyperuricemia | Phase 4 | Completed | Getz Pharma | 50 | 2013-11-01 | 2019-08-01 |
Showing 20 of 24. Sign in to see all of them.
Diabetes Mellitus, Type 2 (9) · Diabetes Mellitus (4) · Hepatitis C (2) · Hypertension (2) · Atherosclerosis (1) · Body Weight Changes (1) · Cardiovascular Diseases (1) · Chronic Disease (1) · Coronary Disease (1) · Diabetes Mellitus, Type 1 (1) · Diabetes, Gestational (1) · Drug-Related Side Effects and Adverse Reactions (1) · Fatty Liver (1) · Glucose Intolerance (1) · Hepatitis C, Chronic (1)
Ribavirin (4) · empagliflozin (4) · Allopurinol (1) · Febuxostat (1) · Insulin (1) · Interferons (1) · Iron-Dextran Complex (1) · Ivabradine (1) · Pioglitazone (1) · Rivaroxaban (1) · Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination (1) · Sofosbuvir (1) · Tablets (1) · Tamsulosin (1) · Vildagliptin (1)
Pakistan (16) · Afghanistan (1) · Japan (1) · Kenya (1) · Nigeria (1) · Sri Lanka (1)
A H Aamir (1) · Asima Khan (1) · Dr. Khawar Mehdi, MD (1) · Ihsan Ullah, MD (1) · Jahanzeb Kamal Khan, MCPS (1) · Khalid Mahmood, FCPS (1) · Madiha Fida, MBBS (1) · Mahwish Raza, Pharm-D (1) · Mansoor Khan (1) · Prof. Dr. Muahmmad Umar, MBBS, FCPS, FACG, AGAF, FRCP (1) · Saeed S Hamid, FRCP (1) · Salman El Khalid, MBBS (1) · Shigeru Saito, MD (1)
PMID 12421831, PMID 15698861, PMID 18349746, PMID 36443769, PMID 37940936, PMID 37984941